Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1974 1
1975 23
1976 42
1977 50
1978 75
1979 84
1980 143
1981 151
1982 160
1983 193
1984 248
1985 259
1986 300
1987 272
1988 297
1989 330
1990 368
1991 306
1992 377
1993 489
1994 478
1995 464
1996 489
1997 510
1998 582
1999 551
2000 660
2001 655
2002 607
2003 664
2004 679
2005 708
2006 685
2007 746
2008 657
2009 645
2010 695
2011 715
2012 659
2013 747
2014 709
2015 679
2016 609
2017 564
2018 550
2019 513
2020 480
2021 437
2022 391
2023 363
2024 279
2025 185

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,953 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A. Lazzeroni M, et al. J Clin Oncol. 2023 Jun 10;41(17):3116-3121. doi: 10.1200/JCO.22.02900. Epub 2023 Mar 14. J Clin Oncol. 2023. PMID: 36917758 Clinical Trial.
Tamoxifen-induced Lung Injury.
Etori S, Nakano R, Kamada H, Hosokawa K, Takeda S, Fukuhara M, Kenmotsu Y, Ishimine A, Sato K. Etori S, et al. Intern Med. 2017 Nov 1;56(21):2903-2906. doi: 10.2169/internalmedicine.8649-16. Epub 2017 Sep 25. Intern Med. 2017. PMID: 28943550 Free PMC article.
Tamoxifen induced hands deformities.
Bendarkawi Y, Cherif Chefchaouni A, Lkhoyaali S, Bechar H, Boudina Y, Abercha Y, Belahcen MJ, Rahali Y. Bendarkawi Y, et al. J Oncol Pharm Pract. 2023 Jul;29(5):1246-1250. doi: 10.1177/10781552221147507. Epub 2022 Dec 26. J Oncol Pharm Pract. 2023. PMID: 36572997
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Fang Z, Corbizi Fattori G, McKerrell T, Boucher RH, Jackson A, Fletcher RS, Forte D, Martin JE, Fox S, Roberts J, Glover R, Harris E, Bridges HR, Grassi L, Rodriguez-Meira A, Mead AJ, Knapper S, Ewing J, Butt NM, Jain M, Francis S, Clark FJ, Coppell J, McMullin MF, Wadelin F, Narayanan S, Milojkovic D, Drummond MW, Sekhar M, ElDaly H, Hirst J, Paramor M, Baxter EJ, Godfrey AL, Harrison CN, Méndez-Ferrer S. Fang Z, et al. Nat Commun. 2023 Nov 25;14(1):7725. doi: 10.1038/s41467-023-43175-5. Nat Commun. 2023. PMID: 38001082 Free PMC article. Clinical Trial.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3. Cell Death Dis. 2024. PMID: 38879508 Free PMC article.
20,953 results
You have reached the last available page of results. Please see the User Guide for more information.